Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

R) group and greater than placebo were dizziness (31 percent vs. 8 percent), headache (13 percent vs. 9 percent), nausea (11 percent vs. 4 percent), and diplopia (11 percent vs. 2 percent).

    -- TEAEs were mild to moderate and appeared to be dose-related.

    -- The incidence of weight gain and other troublesome TEAEs such as
       somnolence and cognitive and psychiatric AEs appeared low:

        -- The incidence of somnolence was 7 percent for the Vimpat(R)-treated
           group vs. 5 percent for placebo

        -- The incidence of memory impairment was 2 percent for both Vimpat(R)
           and placebo groups

        -- The incidence of depression was 2 percent for the Vimpat(R)-treated
           group and 1 percent for placebo

        -- The incidence of weight gain was 1 percent for both Vimpat(R) and
           placebo groups

Poster Session 3, December 8, 2008, 11:30 am - 12:30 pm (Poster 3.245)

V. Biton, N. Fountain, F. Rosenow, A. Gil-Nagel, T. Sullivan, D. Hebert, P. Doty

Clinical Trials, Inc., Little Rock, Arkansas; University of Virginia, Charlottesville, Virginia; Philipps-University, Department of Neurology, Marburg, Germany; Hospital Ruber Internacional, Madrid, Spain; SCHWARZ BIOSCIENCES (a member of the UCB Group), Raleigh, North Carolina

Important safety information about Vimpat(R) in the U.S.

Vimpat(R) tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 17 years and older. Vimpat(R) injection is indicated as short-term replacement when oral administration is not feasible in these patients. Patients should be advised that Vimpat(R) may cause dizziness, ataxia, and syncope. Caution is advised for patients with known cardiac conduction problems, who are taking drugs known to induce PR interval prolongation, or with severe cardiac disease. In p
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... intensively investigated for application as catalysts, sensors, ... components in photonics and molecular electronics. Gaining ... understanding physical and chemical properties, has been ... have demonstrated that high-resolution electron microscopy can ... in which all gold atoms are observed. ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... and China Gel Permeation Chromatography (GPC) Industry Report 2014" ... Global and China Gel Permeation Chromatography (GPC) Industry Report ... state of the global gel permeation chromatography industry with ... provides a basic overview of the industry including definitions, ...
(Date:8/22/2014)... Nerium International, the go-to, buzzworthy skincare ... again. Nerium will showcase its signature NeriumAD® Age-Defying ... Cream to Hollywood’s elite at the official Giving ... Primetime Emmy® Awards. , Developed from cutting-edge research ... show that NeriumAD night cream dramatically reduces the ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  BioSpecifics ... biopharmaceutical company developing first in class collagenase-based products ... or CCH) in the U.S. and XIAPEX ® ... significant results from a randomized, double-blind Phase 2a ... cellulite, or edematous fibrosclerotic panniculopathy. The results showed ...
Breaking Biology Technology:A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy 2Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... a pair of information-carrying molecules: DNA and RNA. These ... they display hereditymeaning they can encode and pass on ... processes of Darwinian evolution. A long-debated question ... molecules other than DNA and RNA. John ...
... new applications based on nanoimprinting techniques (NIL) is evolving at ... be overcome in order to reach the market? How do ... from the industry? What are the tools needed for each ... this topic, i.e. Nanopatterning, Production and Applications based on Nanoimprinting ...
... April 19, 2012 RayBiotech, Inc. today announced that ... diagnostic core facilities at academic and government research institutes ... of the partnership program, core diagnostics facilities will be ... a component of their current services offerings at no ...
Cached Biology Technology:Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 2Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 3Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 4Low-cost optical components through nanoimprinting lithography 2Low-cost optical components through nanoimprinting lithography 3RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program 2
(Date:8/22/2014)... a leading source of information for businesses and professionals, ... Riverside in its 2014 list of "some of the ... generate the list, the company analyzed citation data over ... has had enormous impact. , The following UC Riverside ... the greatest number of highly cited papers in one ...
(Date:8/22/2014)... August 21, 2014 Diabetes affects nearly 10 ... complaints of diabetics: constant finger pricking to test ... Chemical Biology reports the development of a protein ... accurate results for diabetes patients. In the American ... Daunert, Ph.D., shows off her "designer protein" that ...
(Date:8/22/2014)... (Edmonton) Thanks to important discoveries in basic and ... cancer has mobilized into a complex offensive spanning ... of Alberta chemistry lab could help find new ... developed a compound that targets a specific enzyme ... activity in cells from brain tumours. , Chemistry ...
Breaking Biology News(10 mins):5 UC Riverside scientists among world's most influential scientific minds 2New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... Results from two French studies presented today at the ... clinical practice in the treatment of patients with severe ... demonstrated the positive potential of performing liver transplantation for ... the recommended 6-months rule (required minimum of recorded abstinence ...
... Results from two studies presented today at the International ... devices may not confer a survival advantage for severe ... among a small sub-group of patients show promise. ... is valued as a detoxification treatment option for patients ...
... for Chemoreception Sciences (AChemS), a US-based scientific organization, is ... gathering to present new information on the role of ... in humans as well as animals. Smell and taste ... senses serve as important warning systems, alerting us to ...
Cached Biology News:New insights into treatment options for patients suffering from severe alcoholic hepatitis 2New findings on taste and smell 2New findings on taste and smell 3
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Biology Products: